FDA Meeting Dives into New Cancer Drug Approvals
Published Date: 5/8/2025
Notice
Summary
The FDA is holding a public meeting to talk about new and updated cancer drugs, including COLUMVI, DARZALEX FASPRO, mitomycin solution, and TALZENNA capsules. This meeting affects patients, doctors, and drug makers by reviewing important changes that could impact treatment options and costs. The FDA also wants your comments before making final decisions, so now’s the time to speak up!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
FDA Reviews Cancer Drug Applications
The FDA will hold a public Oncologic Drugs Advisory Committee meeting to review applications for COLUMVI (glofitamab) S-001, DARZALEX FASPRO (daratumumab and hyaluronidase) S-029, new drug application 215793 for mitomycin intravesical solution, and supplemental NDA 211651/S-013 for TALZENNA (talazoparib) capsules. The meeting reviews changes that the document says could affect patients, doctors, and drug makers by influencing treatment options and costs. FDA is establishing a public docket and requesting comments before making final recommendations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in